CClinicalTrials.gg
CompletedNCT05295030Updated Dec 27, 2024

Effects of Breast Milk Simulated Infant Formula

An interventional study of Breast milk and Kieember Infant formula, Ruibuen® in Infant Formula and Breast Milk, sponsored by Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 0 Days to 30 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
179
Allocation
Non-randomized
Ages
0 Days to 30 Days
Sex
All
01

Study summary

Objective:The aim of this trial is to assess effects of Kieember and Yashili infant formula on body growth, behavior development, intestinal comfort, infectious diseases, allergic diseases, the absorption of nutrients and gut microbiota as compared to breast-milk in term infants aged 0-3 months.

Participants:144 healthy term infants aged less than 30 days at entry to study. Study Design: A open-label,parallel, controlled trial.

Arms, Groups, and Intervention: (1) Breast milk-fed group: fed with human breast milk; (2) Breast Milk Simulated Formula Group:fed with breast milk simulated infant formula (Ruibuen®Kieember, Phase I); (3) Traditional Formula Group: fed with traditional infant formula (Ruibuen®Yashili, Phase I).

Intervention Duration: 90 days.

Visits: 1month and 3month old.

Outcome measures: (1)Biochemical detection of feces (total fat, fatty acids, calcium, nitrogen);(2)Stool characteristics (frequency, color, volume, and stool consistency);(3)Anthropometric parameters (body length, body weight, and head circumferences);(4)Temperament and adaptive behavior;(5)Gut microbiota;(6)General health and wellbeing;(7)concomitant medications and adverse events.

02

Conditions studied

  • Infant Formula
  • Breast Milk

Keywords

  • gut microbiota
  • temperament
  • body growth
  • fecal residual nutrient
03

In context

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 30 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Term infant: Born at 37-42 gestation weeks
  • Birth weight: 2500-4000g (appropriate for gestational age)
  • The infant is in good health and Apgar after 5 minutes >7
  • The mother had unequivocally decided not to breastfeed (for formula fed infants) or to breastfeed (for human milk fed infants)
  • age at the enrollment: less than 30 days

Exclusion criteria

Exclusion Criteria:

  • The mother is unable to take care of her infant on account of health condition (psychological or physical) or socioeconomic problems
  • The infant is born with a congenital malformation or chromosome abnormality with a clinical significance
  • The infant suffers from a disease requiring mechanical ventilation or medication in the first week of life (not including applying phototherapy of blue to cure neonatal jaundice)
  • The infant whose feeding or normal metabolism is affected by any suspected or unknown metabolic factors or physical limitations
  • The infant has been breastfed for more than 2 weeks (for formula fed infants)
  • Twins or multiple births
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Active comparator
    Breast Milk-Fed Group

    The infants will be breastfed during the study.

    Other: Breast milk

  • Experimental
    Breast Milk Simulated Formula Group

    Kieember Infant formula, Ruibuen®: Infants will be fed Kieember infant formula(Phase I) from baseline (1 month old) to 3 month old.

    Other: Kieember Infant formula, Ruibuen®

  • Experimental
    Traditional Formula Group

    Yashili Infant formula, Ruibuen®: Infants will be fed Yashili infant formula (Phase I) from baseline (1 month old) to 3 month old.

    Other: Yashili Infant formula, Ruibuen®

Interventions

  • OtherBreast milk

    Breast milk: Human breast milk, provided and fed by the corresponding infant's mother

  • OtherKieember Infant formula, Ruibuen®

    Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited

  • OtherYashili Infant formula, Ruibuen®

    Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China

06

What researchers measure

Primary outcomes

  1. Average Change Rate of Gut Microbiota Pattern Score from 1month to 3 month

    Slope of change at 1 and 3 month in gut microbiota pattern score from 16S RNA sequencing.

    Time frame: 1,3 months

  2. Average Change Rate of Fecal Residual Fatty Acid from 1month to 3 month

    Slope of change at 1 and 3 month in Fecal Residual Fatty Acid.

    Time frame: 1,3 months

  3. Average Change Rate of Fecal Residual Nitrogen from 1month to 3 month

    Slope of change at 1 and 3 month in Fecal Residual Nitrogen.

    Time frame: 1,3 months

  4. Average Change Rate of Fecal Residual Calcium from 1month to 3 month

    Slope of change at 1 and 3 month in fecal residual calcium.

    Time frame: 1,3 months

  5. Average Change Rate of body length from 1month to 3 month

    Slope of change at 1 and 3 month in body length.

    Time frame: 1,3 months

  6. Average Change Rate of body weight from 1month to 3 month

    Slope of change at 1 and 3 month in body weigh.

    Time frame: 1,3 months

  7. Average Change Rate of head circumferences from 1month to 3 month

    Slope of change at 1 and 3 month in head circumferences.

    Time frame: 1,3 months

Secondary outcomes

  1. Average Change Rate of Stool Characteristic Index from 1month to 3 month

    Slope of change at 1 and 3 month in Stool Characteristic Index: calculated by using stool color (using sample pictures), stool shape (using sample pictures), and frequency.

    Time frame: 1,3 months

  2. Average Change Rate of an Index of General health and wellbeing from 1month to 3 month

    Slope of change at 1 and 3 month in Index of General health and wellbeing, calculated from diseases (cold, diarrhea,infectious diseases), doctor visits, concomitant medications,etc.

    Time frame: 1,3 months

  3. Average Change Rate of Temperament Score from 1month to 3 month

    Slope of change at 1 and 3 month in Temperament Score assessed by the Early Infant Temperament Scale

    Time frame: 1,3 months

07

Study locations

1 site
  • Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05295030
Lead sponsor
Sun Yat-sen University
Responsible party
Huilian Zhu (Professor, Sun Yat-sen University) — Principal investigator
First posted
Mar 24, 2022
Start date
Apr 10, 2022
Primary completion
Dec 25, 2023
Completion
Dec 25, 2023
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion